Phase 3 Trial Supports Subcutaneous Anifrolumab in Systemic Lupus ErythematosusByChelsie DermanJanuary 14th 2026
The Expanding Lupus Pipeline: Obinutuzumab and What's Next, With Rosalind Ramsey-Goldman, MDByRosalind Ramsey-Goldman, MDJanuary 13th 2026
Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End PointByVictoria JohnsonJanuary 6th 2026